HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Express News | California Institute for Regenerative Medicine Awards Funding for CAR-T Nxc-201 U.S. Al Amyloidosis Clinical Trial (Nexicart-2)
H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
Express News | Immix Biopharma Inc - Data From Ex-US Clinical Trial Reported at Asgct 2024 Showed a 92% Overall Response Rate
Express News | Immix Biopharma Doses 1St Patient in U.S. Al Amyloidosis Trial With CAR-T Nxc-201
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial With CAR-T NXC-201
H.C. Wainwright Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $7
Immix Biopharma Initiated at Buy by HC Wainwright & Co.
Buy Rating for Immix Biopharma Backed by Promising N-GENIUS Platform and Strong NXC-201 Sales Potential
Immix Biopharma Analyst Ratings
Express News | Immix Biopharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma(IMMX.US) Officer Buys US$5,538 in Common Stock
Express News | RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
Immix Biopharma(IMMX.US) Officer Buys US$5,970.03 in Common Stock
Immix Biopharma(IMMX.US) Officer Buys US$5,972.67 in Common Stock
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
Immix Biopharma(IMMX.US) Officer Buys US$10,041.75 in Common Stock
Immix Biopharma(IMMX.US) Officer Buys US$9,659.95 in Common Stock